Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Meets Expectations

Heron Therapeutics (NASDAQ:HRTX) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03), Zacks reports. The business had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same period in the prior year, the business posted ($0.17) EPS. Heron Therapeutics updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Heron Therapeutics Stock Up 2.5 %

HRTX stock opened at $1.24 on Friday. The firm’s fifty day moving average is $1.84 and its 200 day moving average is $2.52. Heron Therapeutics has a 52 week low of $0.72 and a 52 week high of $3.93.

Wall Street Analysts Forecast Growth

HRTX has been the subject of a number of research analyst reports. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC decreased their price target on shares of Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.